Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

April 30, 2027

Conditions
Endometrial CancerLynch Syndrome
Interventions
COMBINATION_PRODUCT

Vaginal DNA swab, microbiome swab and pH test

Participants will receive up to three at-home collection kits with a vaginal swab for DNA collection, a vaginal swab for microbiome sampling, a vaginal pH testing kit, and instructions on how to perform the sample collection. Vaginal DNA will be collected using Zymo DNA/RNA Shield, vaginal microbiome DNA will be collected using Genotek OMNIgene, and vaginal pH will be collected using GYNEX pHem-Alert. Those with abnormal findings will be referred to a gynecologist or gynecologic oncologist for appropriate clinical assessment. Those with negative pathology will remain in the study. The self-collection will be repeated up to two more times, at eight-to-nine-month intervals, up to three successful self-collections.

Trial Locations (1)

V5Z 1M9

RECRUITING

VGH Research Pavilion, Vancouver

All Listed Sponsors
collaborator

Vancouver Coastal Health Research Institute

OTHER

lead

University of British Columbia

OTHER

NCT07194551 - Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire | Biotech Hunter | Biotech Hunter